Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$465.45 ▼ -0.56
(-0.12%)
MKT CAP: $251.94B • VOL: 3.20M
52W L $292 52W H $476
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$391
MEDIAN
$521
MEAN
$531
HIGH
$633
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AMGN TAPE
AMGN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $563.19 | $535.27 | 2025-02-14 | $423.56 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $586.47 | $549.23 | 2025-02-06 | $437.52 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $530.61 | $512.00 | 2025-01-29 | $446.83 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $474.76 | — | 2025-01-17 | $456.14 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $409.60 | $442.18 | 2025-01-09 | $414.25 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $553.89 | $484.07 | 2024-12-18 | $404.94 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $451.49 | $470.10 | 2024-12-04 | $432.87 | -4.3% | 48% | C |